NightstaRx Limited   Report issue

For profit Phase 2 Phase 3
Founded: London United Kingdom (2017)
Status: Acquired by Biogen-IDEC (2019)

Organization Overview

First Clinical Trial
2017
NCT03116113
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Nightstar Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

aav2-rep1 (2 trials)

Drugs in Phase 2 Trials (1)

aav-rpgr (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Choroideremia (Phase 3)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 2